InterSystems announces IRIS FHIR Accelerator Service

InterSystems earlier this week unveiled its new IRIS FHIR Accelerator Service.

As developers work on HL7 FHIR applications for different healthcare use cases, they need a way to manage the data that fuel them. InterSystems designed this new service as a fully managed, enterprise-grade server – providing developers a secure and scalable repository for storing and sharing.

The goal of the technology, built on InterSystems IRIS data platform, is to simplify data storage across IoMT, electronic health records and research databases, according to Scott Gnau, head of data platforms for InterSystems.

Key features include authorization and authentication pre-built with OpenID Connect and OAuth 2.0 using the Cognito authorization server, which includes intuitive methods to select custom FHIR scopes and allows developers to easily configure access control for users and applications.

Others include API keys that authenticate incoming FHIR requests, a developer interface to help with more efficient testing, and support for the latest HL7 FHIR version R4, including the United States Core Data for Interoperability, or USCDI.

In addition to high availability using mirroring, and continuous updates delivered automatically, the IRIS FHIR Accelerator Services supports batch import of FHIR bundles via secure file transfer protocol, or sFTP, making it easy to get started quickly with app development.

This is the newest offering from InterSystems’ Smart Data Services, designed to help customers access the company’s database, interoperability and analytics technologies as smaller, flexible, cloud centric, managed services. Another recent example is HealthShare Message Transformation Services for Amazon HealthLake, which was introduced earlier this summer.

“With a solution like InterSystems IRIS FHIR Accelerator Service, developers have the technology they need to harness interoperability and create solutions to reduce costs, improve patient engagement, facilitate better outcomes, and empower their innovation initiatives,” said Don Woodlock, head of healthcare solutions for InterSystems, in a statement.

“With a fully-managed offering like InterSystems IRIS FHIR Accelerator Service, developers don’t have to worry about traditional infrastructure concerns that come with a FHIR server, including backup and restore, maintenance, and high availability,” added Gnau.

Twitter: @MikeMiliardHITN
Email the writer:

Healthcare IT News is a HIMSS publication.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Higher Estrogen Levels May Protect Against COVID-19 Death thumbnail

Higher Estrogen Levels May Protect Against COVID-19 Death

Women with increased estrogen levels had a lower risk of death from COVID-19, suggesting that female sex hormones may have protective effects against severe illness, according to a cohort study from Sweden. Postmenopausal women who were taking hormone replacement therapy were more than 50% less likely to die from COVID-19 compared with those with natural…
Read More
Vegetarian Spring Rolls thumbnail

Vegetarian Spring Rolls

Ch Giò Chay By: Naomi Sherman Crispy pastry encloses delicious veg-packed filling that tastes so incredibly satisfying that nobody will even notice there is no meat. Ingredients 50g mixed dried mushrooms 50g dried vermicelli noodles 300g tempeh 2 carrots, grated 2 sticks celery, finely chopped 2 medium spring onions, chopped ¼ cup chopped coriander 1
Read More
Clostridia Microbiota Cocktail Prevents Recurrent C. Diff thumbnail

Clostridia Microbiota Cocktail Prevents Recurrent C. Diff

Infectious Disease > General Infectious Disease — 30.5% absolute risk reduction versus placebo with eight-strain oral product by Ingrid Hein, Staff Writer, MedPage Today April 19, 2023 An oral, investigational live biotherapeutic product containing eight strains of commensal Clostridia prevented recurrent Clostridioides difficile infections in a randomized, double-blind phase II trial. In the 79-participant study
Read More
Index Of News